Condition: Colorectal Cancer · Gastric Cancer · Ovarian Cancer · Sponsor: ImmVirx Pty Ltd
This is a Phase 1 open-label, non-randomized, multi-center clinical trial of intratumoral IVX037 as monotherapy and in combination with an immune checkpoint inhibitor in patients with advanced micro satellite-stable (MSS) colorectal cancer, or gastric or ovarian cancer. The study is run in 2 parts. Phase 1a is dose escalation IVX037 monotherapy and Phase 1b is IVX037 with checkpoint inhibitor, sintilimab.
This description comes directly from the study's public registry record.
Oksana Zdanska · +61 (02) 4042 0165 · oksana.zdanska@immvirx.com
Jennifer Rosenthal · +61 (02) 4042 0165 · jen.rosenthal@immvirx.com
Always discuss trial participation with your own doctor first.
| Sydney site | Sydney, New South Wales, Australia | Recruiting |
| South Australia site | Adelaide, South Australia, Australia | Recruiting |
| Melbourne Site | Melbourne, Victoria, Australia | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05427487